Sökresultat - Hina Patel
- Visas 1 - 6 av 6 resultat
-
1
-
2
Primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell... av Andrea Ardizzoni, Sérgio Jobim Azevedo, B. Rubio Viquiera, Delvys Rodríguez‐Abreu, Jorge Alatorre-Alexander, Hans J.M. Smit, Jinming Yu, K. Syrigos, Hina Patel, J. Tolson, Andrés F. Cardona, Pérez Moreno, Thomas Newsom-Davis
Publicerad 2019Artigo -
3
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung can... av Andrea Ardizzoni, Sérgio Jobim Azevedo, Belén Rubio‐Viqueira, Delvys Rodríguez‐Abreu, Jorge Alatorre-Alexander, Hans J.M. Smit, Jinming Yu, Konstantinos Syrigos, Kerstin Trunzer, Hina Patel, Jonathan Tolson, Andrés F. Cardona, Pablo Diego Perez-Moreno, Tom Newsom‐Davis
Publicerad 2021Artigo -
4
IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lun... av Fabrice Barlési, Makoto Nishio, Manuel Cobo, N. Steele, V.V. Paramonov, B. Parente, Rachel Dear, H. Bérard, Nir Peled, Lasika Seneviratne, Editta Baldini, Satoshi Watanabe, Keiko Goto, Diana Mendus, Hina Patel, Yu Deng, Marcin Kowanetz, Tien Hoang, Wei‐Hung Lin, Vassiliki A. Papadimitrakopoulou
Publicerad 2018Artigo -
5
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer av Martin Reck, Thomas Wehler, F. Orlandi, Naoyuki Nogami, Carlo Barone, Denis Moro‐Sibilot, Mikhail Shtivelband, J.L. González-Larriba, J. Rothenstein, Martin Früh, Wei Yu, Yu Deng, Shelley Coleman, Geetha Shankar, Hina Patel, Claudia Kelsch, Anthony Lee, Elisabeth Piault, Mark A. Socinski
Publicerad 2020Artigo -
6
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced... av Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R. Gandara, Santiago Ponce Aix, Ji‐Youn Han, Shirish M. Gadgeel, Toyoaki Hida, Diego Cortinovis, Manuel Cobo, Dariusz M. Kowalski, Filippo de Marinis, Mayank Gandhi, Bradford J. Danner, Christina Matheny, Marcin Kowanetz, Pei He, Federico Felizzi, Hina Patel, Alan Sandler, Marcus Ballinger, Fabrice Barlési
Publicerad 2018Artigo
Sökverktyg:
Relaterade ämnen
Internal medicine
Medicine
Atezolizumab
Cancer
Immunotherapy
Oncology
Adverse effect
Environmental health
Lung cancer
Nivolumab
Population
Surgery
Carboplatin
Chemotherapy
Cisplatin
Clinical trial
Pembrolizumab
Anesthesia
Bevacizumab
Clinical endpoint
Confidence interval
Docetaxel
Etomidate
Hazard ratio
Hydrocortisone
Hypercortisolemia
Interquartile range
Paclitaxel
Pemetrexed
Phases of clinical research